Drug Profile
MK 8325
Alternative Names: MK-8325Latest Information Update: 11 Mar 2016
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 08 Aug 2013 Merck & Co. terminates a phase I trial in Hepatitis C in Belgium and Germany (NCT01554189)
- 01 Mar 2013 Merck & Co. suspends enrolment into its phase I trial in Hepatitis C in Belgium and Germany (NCT01554189)
- 30 Apr 2012 Phase-I clinical trials in Hepatitis C in Germany (PO)